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Supplementary Table 1 
Table of immunohistochemistry results from first round: all markers 
 % Positivity of each marker 

























Breast 35 0 0 0 0 3 3 54 37 77 3 6 51 83 0 0 0 0 14 0 20 0 3 26 0 0 3 60 
Ovary serous 18 0 6 0 0 6 0 6 0 83 94 89 61 89 0 0 0 0 0 0 0 0 0 33 0 0 0 72 
Ovary mucinous 10 10 10 0 0 0 0 10 0 40 30 20 40 40 20 10 30 30 20 10 40 10 10 50 0 0 0 40 
Endometrial adenoca 10 10 0 0 0 0 20 10 0 30 50 90 20 60 0 0 0 10 10 0 0 0 10 100 0 0 0 90 
Pancreas  53 0 0 2 0 4 25 2 0 0 47 53 30 96 0 0 19 60 51 34 55 13 28 68 9 4 0 81 
Ampullary adenoca 6 0 0 0 0 17 33 17 0 0 83 67 0 83 17 17 83 83 67 17 33 0 17 83 0 0 0 83 
Cholangiocarcinoma 10 0 0 0 0 0 10 0 0 0 70 50 10 80 10 10 30 60 90 30 40 10 30 90 20 0 10 80 
Stomach 34 3 0 3 0 9 6 0 0 0 21 9 18 35 18 12 18 47 85 9 21 24 18 44 9 0 18 94 
Esophageal adenoca 21 0 0 0 0 5 0 0 0 0 19 10 0 48 10 5 33 57 57 29 24 0 29 43 10 0 5 71 
Colon 47 0 0 0 0 13 9 9 0 2 2 0 2 4 83 55 68 91 53 4 19 0 6 74 13 0 0 87 
Prostate 18 100 94 11 0 6 6 0 0 11 0 0 0 0 0 0 0 0 6 0 0 0 6 0 0 0 0 67 
Lung 46 0 0 91 89 89 0 4 0 9 39 39 11 91 2 2 2 35 43 7 4 0 13 43 0 0 24 87 
Lung small cell ca 3 0 0 100 33 0 33 0 0 0 0 0 0 0 0 0 0 33 0 0 0 0 0 0 0 0 0 66 
Lung squamous ca 7 0 0 57 57 86 0 0 0 0 14 14 0 43 0 0 0 43 14 0 0 0 0 29 0 0 0 71 
Mesothelioma 6 0 0 0 0 17 0 0 0 0 50 17 0 67 0 0 0 0 17 0 0 0 0 0 0 0 0 50 
Esophageal squ ca 7 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 29 0 0 0 0 0 29 0 0 0 86 
Renal cell ca 15 0 0 0 0 0 0 0 0 0 0 0 13 0 0 0 0 0 7 0 0 0 0 7 0 0 0 80 
Hepatocellular ca 6 0 0 0 0 0 0 0 0 0 0 0 50 0 0 0 0 0 0 0 0 0 0 0 0 0 33 100
 
 
This table provides the immunohistochemistry results from the first round of tissue profiling for 
all 27 markers tested.  The percentage positivity of each marker in each tumor type is given as a 
number and as background shading.  The markers are as follows: PSA, prostate specific antigen; 
PAP, prostatic acid phosphatase;  TTF1, thyroid transcription factor 1; Surf A, surfactant protein 
A; Surf B, surfactant protein B; Chromogran, chromogranin A; GCDFP15, gross cystic disease 
fluid protein 15; Mammaglob, mammaglobin 1; ER, estrogen receptor; Mesothelin; CA125; 
Clusterin; CK7, cytokeratin 7; CDX2; FABP, fatty acid binding protein; CK20, cytokeratin 20;  
CEA, carcinoembryonic antigen; Lysozyme; MUC5, mucin 5AC; pS2/TFF1, trefoil factor 1; 
hSP/TFF2, trefoil factor 2 (human spasmolytic polypeptide); Pep C ICC, pepsinogen C by 
immunohistochemistry; CA19-9; Panc polyp, pancreatic polypeptide; Insulin; Hepar, hepatocyte; 
and Ig kappa, immunoglobulin kappa light chain.  
